Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Mallinckrodt
Moodys
Boehringer Ingelheim
Baxter
Express Scripts

Last Updated: January 19, 2022

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ENTEREG

➤ Subscribe for complete access

« Back to Dashboard

All Clinical Trials for Entereg

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00256932 ↗ Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain Completed GlaxoSmithKline Phase 3 2005-08-01 Adults who are taking opioid therapy for persistent non-cancer pain and have resulting opioid-induced bowel dysfunction (OBD) will be randomized (1:1:1) to one 2 alvimopan arms, or to placebo. The primary objective of this phase 3 confirmatory study is to compare alvimopan with placebo for efficacy in the treatment of OBD. The primary efficacy endpoint is based on frequency of bowel movements. Subjects will be required to: (1) track their bowel movements and other bowel symptoms and (2) attend 6 clinic visits over 4 months.
NCT00256932 ↗ Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain Completed Cubist Pharmaceuticals LLC Phase 3 2005-08-01 Adults who are taking opioid therapy for persistent non-cancer pain and have resulting opioid-induced bowel dysfunction (OBD) will be randomized (1:1:1) to one 2 alvimopan arms, or to placebo. The primary objective of this phase 3 confirmatory study is to compare alvimopan with placebo for efficacy in the treatment of OBD. The primary efficacy endpoint is based on frequency of bowel movements. Subjects will be required to: (1) track their bowel movements and other bowel symptoms and (2) attend 6 clinic visits over 4 months.
NCT00259922 ↗ Alvimopan For The Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain Completed GlaxoSmithKline Phase 3 2005-08-01 Adults who are taking opioid therapy for persistent non-cancer pain and have resulting opioid-induced bowel dysfunction (OBD) will be randomized (1:1:1) to one of 2 alvimopan arms, or to placebo. The primary objective of this phase 3 confirmatory study is to compare alvimopan with placebo for efficacy in the treatment of OBD. The primary efficacy endpoint is based on frequency of bowel movements. Subjects will be required to: (1) track their bowel movements and other bowel symptoms and (2) attend 6 clinic visits over 4 months.
NCT00259922 ↗ Alvimopan For The Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain Completed Cubist Pharmaceuticals LLC Phase 3 2005-08-01 Adults who are taking opioid therapy for persistent non-cancer pain and have resulting opioid-induced bowel dysfunction (OBD) will be randomized (1:1:1) to one of 2 alvimopan arms, or to placebo. The primary objective of this phase 3 confirmatory study is to compare alvimopan with placebo for efficacy in the treatment of OBD. The primary efficacy endpoint is based on frequency of bowel movements. Subjects will be required to: (1) track their bowel movements and other bowel symptoms and (2) attend 6 clinic visits over 4 months.
NCT00708201 ↗ A Study of Alvimopan for the Management of Postoperative Ileus in Participants Undergoing Radical Cystectomy Completed Cubist Pharmaceuticals LLC Phase 4 2009-03-01 This study is being conducted to determine whether alvimopan can accelerate recovery of gastrointestinal function following radical cystectomy when compared with a placebo. Secondary objectives of the study are: - to evaluate the effect of alvimopan on hospital length of stay - to evaluate the effect of alvimopan on prespecified postoperative ileus (POI)-related morbidities - to evaluate the overall and cardiovascular safety of alvimopan
NCT01143259 ↗ Intermountain Healthcare's Enhanced Recovery Protocol for Colon Surgery With and Without Alvimopan Use Completed Cubist Pharmaceuticals LLC N/A 2010-05-01 The purpose of this study is to determine if the addition of alvimopan to our care process model for colon resection patients will decrease length of stay. The care process model is a combination of optimal IV fluid management, early feeding, early ambulation, patient education, and pain management.
NCT01143259 ↗ Intermountain Healthcare's Enhanced Recovery Protocol for Colon Surgery With and Without Alvimopan Use Completed Intermountain Health Care, Inc. N/A 2010-05-01 The purpose of this study is to determine if the addition of alvimopan to our care process model for colon resection patients will decrease length of stay. The care process model is a combination of optimal IV fluid management, early feeding, early ambulation, patient education, and pain management.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Entereg

Condition Name

Condition Name for Entereg
Intervention Trials
Ileus 6
Constipation 3
Bowel Dysfunction 2
Colorectal Surgery 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Entereg
Intervention Trials
Ileus 7
Constipation 3
Intestinal Diseases 2
Gastrointestinal Diseases 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Entereg

Trials by Country

Trials by Country for Entereg
Location Trials
United States 94
Canada 12
Germany 8
United Kingdom 7
Australia 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Entereg
Location Trials
Ohio 5
California 4
North Carolina 4
Indiana 3
Texas 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Entereg

Clinical Trial Phase

Clinical Trial Phase for Entereg
Clinical Trial Phase Trials
Phase 4 5
Phase 3 5
Phase 2 2
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Entereg
Clinical Trial Phase Trials
Completed 9
Terminated 3
Recruiting 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Entereg

Sponsor Name

Sponsor Name for Entereg
Sponsor Trials
Cubist Pharmaceuticals LLC 7
Merck Sharp & Dohme Corp. 5
GlaxoSmithKline 3
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Entereg
Sponsor Trials
Other 15
Industry 15
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Moodys
McKesson
Mallinckrodt
Colorcon
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.